US Stock MarketDetailed Quotes
RENB Renovaro
- 1.820
- -0.085-4.46%
Trading Dec 12 13:17 ET
288.87MMarket Cap-1.86P/E (TTM)
1.970High1.760Low466.59KVolume1.970Open1.905Pre Close860.83KTurnover0.60%Turnover RatioLossP/E (Static)158.72MShares5.25052wk High2.94P/B140.91MFloat Cap0.39552wk Low--Dividend TTM77.42MShs Float13.780Historical High--Div YieldTTM11.02%Amplitude0.393Historical Low1.844Avg Price1Lot Size
About Renovaro Company
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Company Profile
SymbolRENB
Company NameRenovaro
Listing DateDec 10, 2018
Founded2011
CEOMr. David Weinstein
MarketNASDAQ
Employees25
Fiscal Year Ends06-30
Address2080 Century Park East,Suite 906
CityLos Angeles
ProvinceCalifornia
CountryUnited States of America
Zip Code90067
Phone1-305-918-1980
Websitehttp://renovarobio.com
Company Executives
- Name
- Position
- Salary
- David Weinstein
- Chief Executive Officer and Director
- --
- Simon Tarsh
- Interim Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Mark A. Collins, PhD
- Director
- --
- Maurice van Tilburg
- Director
- --
- James A. Mcnulty, C.P.A.
- Director
- --
- Douglas W. Calder
- Director
- --
Heat List
US
Overall
Symbol
Price
% Chg
No Data
